Skip to content
DataLookout
Menu

BRUIN-CLL-314NCT05254743

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 47 versions: 41 with changes below, 6 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Study sites revised (143)v47
  2. Minor Site details revised at 1 of 143 sitesv46
  3. Minor Study sites: 144 to 143v45
  4. Notable Primary completion pushed from Jun 10, 2025 to Oct 2027
    • Enrollment increased: 662 → 737 participants
    • Site details revised at 5 of 144 sites
    v44
  5. Minor Site details revised at 5 of 144 sitesv43
Show 35 earlier versionsHide 35 earlier versions
  1. Minor Site details revised at 5 of 144 sitesv42
  2. Minor Site details revised at 5 of 144 sitesv41
  3. Minor Site details revised at 3 of 144 sitesv40
  4. Minor Site details revised at 12 of 144 sitesv38
  5. Minor Study sites: 148 to 144v37
  6. Minor Study sites: 144 to 148v36
  7. Minor Site details revised at 5 of 144 sitesv35
  8. Minor Study sites: 148 to 144v34
  9. Minor Site details revised at 26 of 148 sitesv32
  10. Minor Site details revised at 9 of 148 sitesv31
  11. Minor Site details revised at 8 of 148 sitesv30
  12. Minor Site details revised at 11 of 148 sitesv29
  13. Minor Site details revised at 1 of 148 sitesv27
  14. Minor Study sites: 177 to 148v25
  15. Notable Trial status: Active, Not Recruiting to Recruiting
    • Site details revised at 177 of 177 sites
    v24
  16. Minor Enrollment target: estimated 725 to confirmed 662v23
  17. Minor Primary completion date changed from estimate of Jun 2025 to Jun 10, 2025v22
  18. Notable Eligibility criteria expanded, about 42 wordsv21 Show 5 more changesShow less
    • Primary endpoints: 1 to 2
    • Enrollment target: 650 to 725
    • Secondary endpoints: 6 to 9
    • Study arms: 2 to 3
    • Collaborators shortened, about 4 words
  19. Minor Primary completion date: Feb 2025 to Jun 2025
    • Study completion date: Aug 2028 to Jan 2028
    v18
  20. Notable Eligibility criteria expanded, about 1 word
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 177 of 177 sites
    v17
  21. Notable Primary completion date: Mar 24, 2028 to Feb 2025
    • Study sites: 204 to 177
    • Study completion date: Mar 24, 2029 to Aug 2028
    v16
  22. Minor Study sites revised (204)v15
  23. Minor Study sites: 198 to 204v14
  24. Minor Study sites: 185 to 198v13
  25. Notable Eligibility criteria expanded, about 65 words
    • Primary endpoint revised
    • Study sites: 77 to 185
    • Secondary endpoints: 3 to 6
    v12
  26. Minor Study sites: 69 to 77v11
  27. Minor Study sites: 65 to 69v10
  28. Minor Study sites: 61 to 65v9
  29. Minor Study sites: 37 to 61v8
  30. Minor Study sites: 26 to 37v7
  31. Minor Study sites: 1 to 26v6
  32. Minor Collaborators expanded, about 4 wordsv5
  33. Minor Study sites: 22 to 1v4
  34. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 22
    • Start date changed from estimate of Apr 2022 to Jul 22, 2022
    v3
  35. Minor Study sites: 0 to 1
    • Primary completion date: Mar 1, 2028 to Mar 24, 2028
    • Study completion date: Mar 1, 2029 to Mar 24, 2029
    • Start date: Apr 15, 2022 to Apr 2022
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (Cri), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 1
Timeframe: Baseline to best overall response the best response recorded from Cycle 1 Day 1 until data cutoff date, PD, or start of new anticancer treatment, whichever is the earliest] (approximately 3 years and 5 months)
Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (CRi), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 2
Timeframe: Baseline to best overall response the best response recorded from Cycle 1 Day 1 until data cutoff date, PD, or start of new anticancer treatment, whichever is the earliest (Approximately 2 years and 3 months)

Secondary (9)

IRC-assessed Progression-Free Survival (PFS)
Investigator assessed Progression-Free Survival (PFS)
Event-Free Survival (EFS)
Duration of Response (DOR)
Overall Survival (OS)
Show 4 moreShow less
Time to Next Treatment (TTNT)
Time to Worsening (TTW) of CLL/SLL Related Symptoms
Comparative Tolerability
Percentage of Participants Achieving DOR Part 2

Arms and interventions

Pirtobrutinib Part 1Experimental

Participants will receive pirtobrutinib orally.

Ibrutinib Part 1Active comparator

Participants will receive ibrutinib orally.

Pirtobrutinib Part 2Experimental

Participants will receive pirtobrutinib orally.

Drugs: Pirtobrutinib, Ibrutinib

Sites

143 sites in 23 countries

United States 19, China 18, Brazil 14, Spain 13, France 10, Poland 8, Turkey (Türkiye) 7, Czechia 6, Italy 6, Chile 4, Germany 4, New Zealand 4, South Korea 4, Taiwan 4, United Kingdom 4, Argentina 3, Australia 3, Canada 3, Belgium 2, Hungary 2, Israel 2, Japan 2, Austria 1